Next Article in Journal
Validation of a UPLC-MS/MS Method for Multi-Matrix Biomonitoring of Alternaria Toxins in Humans
Previous Article in Journal
Effects of Deoxynivalenol and Its Acetylated Derivatives on Lipid Metabolism in Human Normal Hepatocytes
Previous Article in Special Issue
Beyond Pain: The Effects of OnabotulinumtoxinA Therapy on Sensitization and Interictal Symptoms in Chronic Migraine
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Toxins
Volume 16
Issue 7
10.3390/toxins16070295
toxins-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Systematic Review

Onabotulinumtoxina in the Prevention of Migraine in Pediatric Population: A Systematic Review

by
Artemis Mavridi
1,
Aine Redmond
2,
Paraschos Archontakis-Barakakis
3,
Petya Bogdanova-Mihaylova
2,
Christina I. Deligianni
4,5,
Dimos D. Mitsikostas
4,* and
Theodoros Mavridis
2,4,*
1
First Department of Pediatrics, School of Medicine, “Aghia Sofia” Children’s Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece
2
Department of Neurology, Tallaght University Hospital, D24 NR0A Dublin, Ireland
3
Redington-Fairview General Hospital, Skowhegan, ME 04976, USA
4
1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, 11528 Athens, Greece
5
Neurology Department, Athens Naval Hospital, Deinokratous 70, 11521 Athens, Greece
*
Authors to whom correspondence should be addressed.
Toxins 2024, 16(7), 295; https://doi.org/10.3390/toxins16070295
Submission received: 21 April 2024 / Revised: 26 May 2024 / Accepted: 26 June 2024 / Published: 28 June 2024
(This article belongs to the Special Issue Botulinum Toxin and Migraine: Goals and Perspectives (Volume II))
Browse Figure
Review Reports Versions Notes

Abstract

Migraine is a leading cause of disability worldwide, yet it remains underrecognized and undertreated, especially in the pediatric and adolescent population. Chronic migraine occurs approximately in 1% of children and adolescents requiring preventive treatment. Topiramate is the only FDA-approved preventative treatment for children older than 12 years of age, but there is conflicting evidence regarding its efficacy. OnabotulinumtoxinA is a known and approved treatment for the management of chronic migraine in people older than 18 years. Several studies examine its role in the pediatric population with positive results; however, the clear-cut benefit is still unclear. OnabotulinumtoxinA seems not only to improve disability scores (PedMIDAS) but also to improve the quality, characteristics, and frequency of migraines in the said population. This systematic review aims to summarize the evidence on the efficacy, dosing, administration, long-term outcomes, and safety of onabotulinumtoxinA in pediatric and adolescent migraine. Eighteen studies met the eligibility criteria and were included in this review. The mean monthly migraine days (MMDs), decreased from of 21.2 days per month to 10.7 after treatment. The reported treatment-related adverse effects were mild and primarily injection site related and ranged from 0% to 47.0%. Thus, this review provides compelling evidence suggesting that OnabotulinumtoxinA may represent a safe and effective preventive treatment option for pediatric migraine.
Keywords: OnabotulinumtoxinA; pediatric migraine; PREEMPT; migraine treatment; chronic migraine; preventive treatment OnabotulinumtoxinA; pediatric migraine; PREEMPT; migraine treatment; chronic migraine; preventive treatment

Share and Cite

MDPI and ACS Style

Mavridi, A.; Redmond, A.; Archontakis-Barakakis, P.; Bogdanova-Mihaylova, P.; Deligianni, C.I.; Mitsikostas, D.D.; Mavridis, T. Onabotulinumtoxina in the Prevention of Migraine in Pediatric Population: A Systematic Review. Toxins 2024, 16, 295. https://doi.org/10.3390/toxins16070295

AMA Style

Mavridi A, Redmond A, Archontakis-Barakakis P, Bogdanova-Mihaylova P, Deligianni CI, Mitsikostas DD, Mavridis T. Onabotulinumtoxina in the Prevention of Migraine in Pediatric Population: A Systematic Review. Toxins. 2024; 16(7):295. https://doi.org/10.3390/toxins16070295

Chicago/Turabian Style

Mavridi, Artemis, Aine Redmond, Paraschos Archontakis-Barakakis, Petya Bogdanova-Mihaylova, Christina I. Deligianni, Dimos D. Mitsikostas, and Theodoros Mavridis. 2024. "Onabotulinumtoxina in the Prevention of Migraine in Pediatric Population: A Systematic Review" Toxins 16, no. 7: 295. https://doi.org/10.3390/toxins16070295

APA Style

Mavridi, A., Redmond, A., Archontakis-Barakakis, P., Bogdanova-Mihaylova, P., Deligianni, C. I., Mitsikostas, D. D., & Mavridis, T. (2024). Onabotulinumtoxina in the Prevention of Migraine in Pediatric Population: A Systematic Review. Toxins, 16(7), 295. https://doi.org/10.3390/toxins16070295

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop